• <delect id="q1kcn"></delect>

    <acronym id="q1kcn"></acronym>
    
    
  • For the latest updates on our ongoing response to COVID-19, please click here.

    Pipeline

    The impossible is simply what hasn’t been achieved yet. Gilead’s research and development program is focused on what’s next. We discover, identify and evaluate investigational compounds that show potential to advance the treatment of life-threatening diseases.

    The safety and efficacy of the following investigational compounds or investigational uses of marketed products have not been established. These uses have not been approved by the U.S. Food and Drug Administration or other regulatory authorities.

    Pipeline

    Viral?Diseases

    • Biktarvy

      HIV treatment pediatric1

      Phase 1
      Phase 2
      Phase 3
    • Capsid inhibitor (GS-6207)

      HIV HTE2

      Phase 1
      Phase 2
      Phase 3
    • Capsid inhibitor (GS-6207)

      HIV treatment na?ve

      Phase 1
      Phase 2
      Phase 3
    • Vesatolimod (GS-9620, TLR-7 agonist)

      HIV cure

      Phase 1
      Phase 2
      Phase 3
    • Elipovimab (GS-9722, bNab)

      HIV cure

      Phase 1
      Phase 2
      Phase 3
    • Selgantolimod (GS-9688, TLR-8 agonist)

      HBV cure

      Phase 1
      Phase 2
      Phase 3
    • PD-L1 inhibitor (GS-4224)

      HBV cure

      Phase 1
      Phase 2
      Phase 3

    1 Biktarvy HIV treatment pediatric label extension.

    2 Registrational for heavily treatment-experienced (HTE) patients.

    Inflammatory diseases

    • Filgotinib (GS-6034, JAK-1 inhibitor)

      Rheumatoid arthritis

      Phase 1
      Phase 2
      Phase 3
    • Filgotinib (GS-6034, JAK-1 inhibitor)

      Ulcerative colitis

      Phase 1
      Phase 2
      Phase 3
    • Filgotinib (GS-6034, JAK-1 inhibitor)

      Crohn's disease

      Phase 1
      Phase 2
      Phase 3
    • Filgotinib (GS-6034, JAK-1 inhibitor)

      Psoriatic arthritis

      Phase 1
      Phase 2
      Phase 3
    • Filgotinib (GS-6034, JAK-1 inhibitor)

      Ankylosing spondylitis

      Phase 1
      Phase 2
      Phase 3
    • Filgotinib (GS-6034, JAK-1 inhibitor)

      Uveitis

      Phase 1
      Phase 2
      Phase 3
    • TPL2 inhibitor (GS-4875)

      Ulcerative colitis

      Phase 1
      Phase 2
      Phase 3
    • GLPG-19721

      Osteoarthritis

      Phase 1
      Phase 2
      Phase 3
    • GLPG-05551

      Inflammatory diseases

      Phase 1
      Phase 2
      Phase 3
    • GLPG-33121

      Inflammatory diseases

      Phase 1
      Phase 2
      Phase 3
    • GLPG-39701

      Inflammatory diseases

      Phase 1
      Phase 2
      Phase 3
    • GLPG-36671

      Inflammatory diseases

      Phase 1
      Phase 2
      Phase 3

    1 Optionable partner program.

    Fibrotic Diseases

    • Cilofexor (GS-9674, FXR agonist)

      PSC

      Phase 1
      Phase 2
      Phase 3
    • GLPG-16901

      Idiopathic Pulmonary Fibrosis

      Phase 1
      Phase 2
      Phase 3
    • Cilofexor (FXR agonist)

      NASH

      Phase 1
      Phase 2
      Phase 3
    • Firsocostat (ACC inhibitor)

      NASH

      Phase 1
      Phase 2
      Phase 3
    • Selonsertib (ASK1 inhibitor) combinations

      NASH

      Phase 1
      Phase 2
      Phase 3
    • Selonsertib (GS-4997, ASK1 inhibitor)

      DKD

      Phase 1
      Phase 2
      Phase 3
    • GLPG-16901

      Systemic sclerosis

      Phase 1
      Phase 2
      Phase 3
    • GLPG-12052

      Idiopathic pulmonary fibrosis

      Phase 1
      Phase 2
      Phase 3

    1 Optioned parter program.

    2 Optionable partner program.

    Oncology

    • KTE-X19

      MCL

      Phase 1
      Phase 2
      Phase 3
    • Axi-cel

      2L DLBCL

      Phase 1
      Phase 2
      Phase 3
    • Axi-cel

      Indolent NHL

      Phase 1
      Phase 2
      Phase 3
    • Axi-cel

      1L DLBCL

      Phase 1
      Phase 2
      Phase 3
    • Axi-cel

      DLBCL (+rituximab or lenalidomide)

      Phase 1
      Phase 2
      Phase 3
    • KTE-X19

      Adult ALL

      Phase 1
      Phase 2
      Phase 3
    • KTE-X19

      Pediatric ALL

      Phase 1
      Phase 2
      Phase 3
    • KTE-X19

      CLL

      Phase 1
      Phase 2
      Phase 3
    • Axi-cel

      DLBCL (utomilumab)

      Phase 1
      Phase 2
      Phase 3
    • KITE-718 (MAGE A3/A6)

      Solid tumor

      Phase 1
      Phase 2
      Phase 3
    • KITE-439 (HPV E7)

      Solid tumor

      Phase 1
      Phase 2
      Phase 3
    • Oral PD-L1 inhibitor (GS-4224)

      Solid tumor

      Phase 1
      Phase 2
      Phase 3
    • anti-CD73/TGF? TRAP (GS-1423)1

      Solid tumor

      Phase 1
      Phase 2
      Phase 3
    • Bi-specific mAb (AGEN1223)2,3,4

      Multiple

      Phase 1
      Phase 2
      Phase 3
    • Anti-CD137 mAb mAb (AGEN2373)3,4

      Multiple

      Phase 1
      Phase 2
      Phase 3

    1 TME conditioning anti-CD73/TGF? TRAP bifunctional fusion protein (GS-1423).

    2 Bi-specific mAb targeting immunosuppressive regulatory T cells (AGEN1223).

    3 Exclusive option to license right from Agenus upon proof of concept data.

    4 Optionable partner program. ALL - Acute lymphocytic leukemia. CLL - Chronic lymphocytic leukemia. DLBCL - Diffuse large B-cell lymphoma. iNHL - Indolent non-Hodgkin lymphoma. MCL - Mantle cell lymphoma. r/r - relapsed refractory. iNHL - Indolent non-Hodgkin lymphoma.

    2019国产视频区